Literature DB >> 26637727

Acquired bleeding disorders in the elderly.

Rebecca Kruse-Jarres1.   

Abstract

The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow. Generally, this predisposes the elderly to thrombosis rather than bleeding. It often necessitates antiplatelet or anticoagulation therapy, which can cause significant bleeding problems in an aging population. Additionally, changing renal function, modification in immune regulation, and a multitude of other disease processes, can give rise to acquired bleeding disorders. Bleeding can prove difficult to treat in a dynamic environment and in a population that may have underlying thrombotic risk factors.This article discusses some specific challenges of acquired bleeding arising in the elderly. The use of anticoagulation and nonsteroidal anti-inflammatory medications is prevalent in the treatment of the elderly and predisposes them to increased bleeding risk as their physiology changes. When prescribing and monitoring these therapies, it is exceedingly important to weigh thrombotic versus bleeding risks. There are additional rare acquired bleeding disorders that predominantly affect the elderly. One of them is acquired hemophilia, which is an autoimmune disorder arising from antibodies against factor VIII. The treatment challenge rests in the use of hemostatic agents in a population that is already at increased risk for thrombotic complications. Another rare disorder of intensifying interest, acquired von Willebrand syndrome, has a multitude of etiologic mechanisms. Understanding the underlying pathophysiology is essential in making a treatment decision for this disorder.
© 2015 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26637727     DOI: 10.1182/asheducation-2015.1.231

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  9 in total

Review 1.  Practical Management of Anaesthesia in the Elderly.

Authors:  Camilla Strøm; Lars Simon Rasmussen; Jacob Steinmetz
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

Review 2.  [Pathophysiology of bleeding].

Authors:  Sirak Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2021-08-17       Impact factor: 0.840

3.  Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.

Authors:  Yukiko Komeno; Naoki Shibuya; Hideki Uryu; Haruki Yamada; Takeo Toda; Masayuki Shibasaki; Shinji Kunishima; Kuniko Iihara; Tomiko Ryu
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

Review 4.  Von Willebrand disease in the elderly: clinical perspectives.

Authors:  John Chapin
Journal:  Clin Interv Aging       Date:  2018-08-31       Impact factor: 4.458

5.  Rotational thromboelastometry-guided perioperative management of coagulation in a patient with Heyde's syndrome undergoing transcatheter aortic valve implantation.

Authors:  Kumi Fukuhara; Takashi Kondo; Hirotsugu Miyoshi; Hiroshi Hamada; Masashi Kawamoto
Journal:  JA Clin Rep       Date:  2019-01-11

6.  Mild bleeding disorders in adults.

Authors:  Dongmei Sun; Chai W Phua
Journal:  CMAJ       Date:  2021-03-08       Impact factor: 8.262

7. 

Authors:  Dongmei Sun; Chai W Phua
Journal:  CMAJ       Date:  2021-05-25       Impact factor: 8.262

8.  Glycine improves peritoneal vasoreactivity to dialysis solutions in the elderly.

Authors:  El Rasheid Zakaria; Bellal Joseph; Mohammad Hamidi; Muhammad Zeeshan; Abdelrahman Algamal; Faheem Sartaj; Maha Althani; Tassnim Fadl; Dana Madan
Journal:  Qatar Med J       Date:  2019-12-24

Review 9.  Platelets in aging and cancer-"double-edged sword".

Authors:  Alessandra V S Faria; Sheila S Andrade; Maikel P Peppelenbosch; Carmen V Ferreira-Halder; Gwenny M Fuhler
Journal:  Cancer Metastasis Rev       Date:  2020-09-01       Impact factor: 9.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.